Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 801-809

  Assinger, Alice ^a,b   Kral, Julia B ^b   Yaiw, Koon C ^a   Schrottmaier, Waltraud C ^b   Kurzejamska, Ewa ^a,c   Wang, Yajuan ^a,d   Mohammad, Abdul Aleem ^a   Religa, Piotr ^a   Rahbar, Afsar ^a   Schabbauer, Gernot ^b   Butler, Lynn M ^a   Söderberg Naucler, Cecilia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d SHANDONG UNIVERSITY   (China)

Author keywords

atherosclerosis; blood platelets; cytomegalovirus; toll like receptors

Indexed keywords

CD40 LIGAND; INTERLEUKIN 1BETA; TOLL LIKE RECEPTOR 2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DISEASE EXACERBATION; HUMAN CYTOMEGALOVIRUS; IN VIVO STUDY; INFLAMMATION; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; TISSUE INJURY; UPREGULATION; VIRUS CELL INTERACTION; VIRUS ISOLATION;

ATHEROSCLEROSIS; BLOOD PLATELETS; CYTOMEGALOVIRUS; TOLL-LIKE RECEPTORS;

ADENOSINE DIPHOSPHATE; ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; CD40 LIGAND; CELL DEGRANULATION; CELLS, CULTURED; CYTOMEGALOVIRUS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHIL ACTIVATION; NEUTROPHILS; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897403045     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303287     Document Type: Article

References (37)

1. Söderberg-Nauclér C. Does cytomegalovirus play a causative role in the development of various infammatory diseases and cancer? J Intern Med. 2006;259:219-246.
2. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991;72(Pt 9):2059-2064.
3. Söderberg-Nauclér C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119-126.
4. Arora N, Novak Z, Fowler KB, Boppana SB, Ross SA. Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis. 2010;202:1800-1803.
5. von Hundelshausen P, Weber C. Platelets as immune cells: bridging infammation and cardiovascular disease. Circ Res. 2007;100:27-40.
6. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res. 2005;96:612-616.
7. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol. 2004;25:489-495.
8. Agbanyo FR, Wasi S. Human cytomegalovirus interaction with platelets and adhesive glycoproteins: signifcance in viral pathogenesis. J Infect Dis. 1994;170:1120-1127.
9. Rossini G, Cerboni C, Santoni A, Landini MP, Landolfo S, Gatti D, Gribaudo G, Varani S. Interplay between human cytomegalovirus and intrinsic/innate host responses: a complex bidirectional relationship. Mediators Infamm. 2012;2012:607276.
10. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol. 2006;177:7094-7102.
11. Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW. Human cytomegalovirus activates infammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003;77:4588-4596.
12. Varani S, Cederarv M, Feld S, Tammik C, Frascaroli G, Landini MP, Söderberg-Nauclér C. Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. J Immunol. 2007;179:7767-7776.
13. Shiraki R, Inoue N, Kawasaki S, Takei A, Kadotani M, Ohnishi Y, Ejiri J, Kobayashi S, Hirata K, Kawashima S, Yokoyama M. Expression of Toll-like receptors on human platelets. Thromb Res. 2004;113:379-385.
14. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestel FP, Ni H, Lazarus AH, Freedman J, Semple JW. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-Alpha production in vivo. Blood. 2006;107:637-641.
15. Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol. 2005;83:196-198.
16. Ward JR, Bingle L, Judge HM, Brown SB, Storey RF, Whyte MK, Dower SK, Buttle DJ, Sabroe I. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost. 2005;94:831-838.
17. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. Blood. 2005;106:2417-2423.
18. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutro-phil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13:463-469.
19. Blair P, Rex S, Vitseva O, Beaulieu L, Tanriverdi K, Chakrabarti S, Hayashi C, Genco CA, Iafrati M, Freedman JE. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinfammatory response through activation of phosphoinositide 3-kinase. Circ Res. 2009;104:346-354.
20. Thon JN, Peters CG, Machlus KR, Aslam R, Rowley J, Macleod H, Devine MT, Fuchs TA, Weyrich AS, Semple JW, Flaumenhaft R, Italiano JE Jr. T granules in human platelets function in TLR9 organization and signaling. J Cell Biol. 2012;198:561-574.
21. Assinger A, Laky M, Schabbauer G, Hirschl AM, Buchberger E, Binder BR, Volf I. Effcient phagocytosis of periodontopathogens by neutro-phils requires plasma factors, platelets and TLR2. J Thromb Haemost. 2011;9:799-809.
22. Fung CY, Jones S, Ntrakwah A, Naseem KM, Farndale RW, Mahaut-Smith MP. Platelet Ca(2+) responses coupled to glycoprotein VI and Toll-like receptors persist in the presence of endothelial-derived inhibitors: roles for secondary activation of P2X1 receptors and release from intracellular Ca(2+) stores. Blood. 2012;119:3613-3621.
23. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-And-effect relationship? Lancet Infect Dis. 2002;2:539-549.
24. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis. 2000;181:717-720.
25. Linden MD, Furman MI, Frelinger AL 3rd, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007;5:761-765.
26. Dumortier J, Streblow DN, Moses AV, Jacobs JM, Kreklywich CN, Camp D, Smith RD, Orloff SL, Nelson JA. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J Virol. 2008;82:6524-6535.
27. Holm PW, Slart RH, Zeebregts CJ, Hillebrands JL, Tio RA. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann Med. 2009;41:257-264.
28. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an infammatory reaction of endothelial cells. Nature. 1998;391: 591-594.
29. Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and infammatory processes in atherosclerosis. Blood. 2010;116:4317-4327.
30. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-203.
31. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002;106:981-986.
32. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Müller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost. 1998;80:1008-1014.
33. Hristov M, Gümbel D, Lutgens E, Zernecke A, Weber C. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation. 2010;121:315-324.
34. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-2147.
35. Vliegen I, Herngreen SB, Grauls GE, Bruggeman CA, Stassen FR. Mouse cytomegalovirus antigenic immune stimulation is suffcient to aggravate atherosclerosis in hypercholesterolemic mice. Atherosclerosis. 2005;181:39-44.
36. Stassen FR, Vega-Córdova X, Vliegen I, Bruggeman CA. Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J Clin Virol. 2006;35:349-353.
37. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005;115:3149-3156.